RESUMEN
Objectives: The aim of this study was to examine the effect of surgery type and hormone therapy on the general quality of life in breast cancer patients receiving radiotherapy. Material and Methods: A total of 109 patients were included in the study. As data collection tools in the research, a form stating the demographic and clinical features was used in the first part, and in the second part, "EORTC QLQ-C30" developed by the European Organization for Research and Treatment of Cancer and "EORTC QLQ-BR23" Turkish quality of life forms specific to breast cancer were used. The patients were asked to fill in the questionnaire forms on the first day, the last day of radiotherapy and three months after the end of the treatment. Results: Mean age of this study was 54.8 ± 12.1 years. In the questionnaires made on the first day, last day and three months after radiotherapy, the highest score according to the EORTC QLQ-C30 scale was in social and cognitive function, and in sexual life on the EORTC QLQ-BR23 scale. According to multiple comparison test and comparing the first day of radiotherapy and three months after radiotherapy, there was a significant difference in patients' physical function average (p= 0.049), future expectation (p= 0.033), sexual life (p= 0.029), sexual satisfaction (p <0.001), and hair loss (p= 0.011), and arm related problems (p <0.001). According to the analysis of variance in repeated measurements, physical function, sexual life, side effects, hair loss, dyspnea, and future expectation were statistically significant according to the type of surgery, and for hormone therapy, sexual life, hair loss, constipation and financial difficulty were found statistically significant. Conclusion: It was observed that other than radiotherapy, hormone therapy and surgical techniques were also effective on the quality of life in patients receiving radiotherapy for breast cancer.
RESUMEN
Background: Targeting autophagy at gene level may be promising in multiple myeloma (MM) treatment depending on chromosomal abnormality (ABN) status. Objectives: We aimed to investigate the role of ABN on survival of MM patients and to identify prognosis related autophagy-related genes (ARGs) for patients with or without ABN. Methods: Gene intensity values of 222 ARG for 548 MM patients were obtained from the Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) platform containing 54,675 probes (GSE24080). A dataset containing data from 1576 MM patients with 1q21 amplification (GSE4204, GSE4452, GSE4581, and GSE2658) was used for validation. Survival analysis of the patients was analyzed using univariate and multivariate Cox regression method with the help of R3.53 programming language and Kaplan-Meier graphics were created. The Gene Ontology enRIchmentanaLysis and visuaLizAtion (GOrilla) tool was used to define the related biological processes and pathways. Results: The overall survival (OS) and event-free survival (EFS) in all MM patients were strongly influenced by ABN. In the group of patients with ABN, 41 ARGs were found to be important in prognosis, whereas in the group of patients without ABN, 13 ARGs were found to be important in prognosis. CDKN1A, FKBP1B, FOXO3, and NCKAP1 ARGs were commonly significant in both groups and found to be survival triggering. Conclusions: The classification of MM patients according to the absence or presence of ABN is important in the determination of survival status. Detection of survival related ARGs in patients with chromosomal anomalies may be a new therapeutic target in treatment.
Asunto(s)
Carcinoma Hepatocelular , Quimioembolización Terapéutica/métodos , Sistemas de Liberación de Medicamentos/métodos , Neoplasias Hepáticas , Radiocirugia/métodos , Radioisótopos de Itrio/farmacología , Antineoplásicos/farmacología , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/terapia , Terapia Combinada/métodos , Humanos , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/terapia , Microesferas , Radiofármacos/farmacología , Medición de Riesgo , Resultado del TratamientoAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Humanos , Compuestos de Fenilurea/administración & dosificación , Piridinas/administración & dosificación , Quinolinas/administración & dosificación , Tasa de Supervivencia , Resultado del TratamientoAsunto(s)
Lesión Pulmonar/etiología , Oxaliplatino/efectos adversos , Traumatismos por Radiación/etiología , Antineoplásicos/efectos adversos , Humanos , Pulmón/efectos de los fármacos , Pulmón/efectos de la radiación , Lesión Pulmonar/inducido químicamente , Traumatismos por Radiación/inducido químicamenteAsunto(s)
Neoplasias Encefálicas/secundario , Neoplasias Encefálicas/terapia , Irradiación Craneana/métodos , Inhibidores de Proteínas Quinasas/uso terapéutico , Neoplasias Encefálicas/patología , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/radioterapia , Ensayos Clínicos Fase I como Asunto , Ensayos Clínicos Fase II como Asunto , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/radioterapiaAsunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias de Cabeza y Cuello/enzimología , Fosfohidrolasa PTEN/metabolismo , Infecciones por Papillomavirus/enzimología , Femenino , Neoplasias de Cabeza y Cuello/patología , Neoplasias de Cabeza y Cuello/radioterapia , Neoplasias de Cabeza y Cuello/virología , Humanos , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/patología , Infecciones por Papillomavirus/virología , Tolerancia a RadiaciónAsunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Femenino , Humanos , Terapia Molecular Dirigida/efectos adversos , Terapia Molecular Dirigida/métodos , Traumatismos por Radiación/etiología , Radioterapia/efectos adversos , Radioterapia/métodos , Análisis de Supervivencia , Trastuzumab/efectos adversos , Trastuzumab/uso terapéuticoAsunto(s)
Antagonistas de Andrógenos/administración & dosificación , Prostatectomía/métodos , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/cirugía , Terapia Recuperativa/métodos , Humanos , Masculino , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/radioterapiaAsunto(s)
Biomarcadores de Tumor/genética , Regulación Neoplásica de la Expresión Génica/efectos de la radiación , Neoplasias de la Próstata/radioterapia , Tolerancia a Radiación/genética , Radioterapia/efectos adversos , Transducción de Señal/efectos de la radiación , Serina-Treonina Quinasas TOR/genética , Humanos , Masculino , Fosfohidrolasa PTEN/genética , Fosfatidilinositol 3-Quinasas/genética , Pronóstico , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Proteínas Proto-Oncogénicas c-akt/genéticaRESUMEN
Objective: The objective of this study was to investigate the correlation of height with prognosis and other prognostic factors in Turkish breast cancer cases. Materials and Methods: We retrospectively reviewed a total of 393 women aged between 26 and 88 years, diagnosed with stage 1-3 invasive ductal breast cancer, treated and followed-up in Kayseri Education and Research Hospital. Findings: The mean age at admission was 55.7 years; 77.6% were aged under 65, 56.7% were postmenopausal, 97.4% had undergone modified radical mastectomy, 47.3% were AJCC stage II, 36.8% N0, 46.0% grade II, 95.4% had received chemotherapy, 81.1% radiotherapy and 71.5% hormonotherapy. Height was under 151 cm in 20.8 %, 151-160 cm in 57.3 % and over 161 in 21.9 %. Follow-up duration differed between 0.3 and 195.3 months. Mean overal survival (OS) was 125.0 (65.6-184.3) months and progression free survival was 91.5 (37.7-145.2) months, with a tendency for better survival in taller individuals but no signficant variation between height groups. The 5 and 10-year OS rates were 74.5% and 56.4%, and PFS rates were 64.5% and 49.2%. Regarding association of height with other prognostic factors, a significant correlation was found between height and AJCC stage (p= 0.011) and estrogen status (ER) (p= 0.043). Conclusion: In conclusion, overal survival was found to be longer in patients with a height between 151 and 160 cm than those under 151 cm and over 161 cm. The reason for not obtaining significant results might be a relatively small number of patients and lack of the evaluation of clinical and pathologic characteristics together with anthropometric measurements in the patient population. Further studies are warranted to clarify any association.